Time needed to heal TalkMed's wound from CEO Ang's suspension: RHB
Michelle Zhu • • 2 min read
SINGAPORE (Apr 27): RHB is maintaining its “neutral” call on TalkMed Group with a lower target price of 70 cents from 72 cents previously after the group reported a weak 1Q18 set of financial results.
Follow us on Facebook and join our Telegram channel for the latest updates.
SINGAPORE (Apr 27): RHB is maintaining its “neutral” call on TalkMed Group with a lower target price of 70 cents from 72 cents previously after the group reported a weak 1Q18 set of financial results.
To recap, the private healthcare services group saw its topline fall 25.7% on-year due to the eight-month suspension of its key revenue contributor and CEO, Ang Peng Tiam, who only resumed his medical duties last month on Mar 25.
Never miss out on important financial news and get daily updates today
×
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
